Name | Number of supported studies | Average coverage | |
---|---|---|---|
erythroblast | 4 studies | 55% ± 25% | |
erythrocyte | 4 studies | 51% ± 11% | |
GABAergic neuron | 3 studies | 32% ± 3% | |
glutamatergic neuron | 3 studies | 38% ± 3% | |
megakaryocyte-erythroid progenitor cell | 3 studies | 56% ± 18% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 100% | 928.63 | 578 / 578 | 99% | 26.97 | 1149 / 1155 |
brain | 100% | 601.58 | 2631 / 2642 | 100% | 20.60 | 702 / 705 |
pancreas | 100% | 746.79 | 327 / 328 | 99% | 22.44 | 177 / 178 |
adrenal gland | 100% | 2355.40 | 258 / 258 | 99% | 30.29 | 228 / 230 |
intestine | 100% | 837.92 | 966 / 966 | 99% | 26.84 | 522 / 527 |
breast | 100% | 823.24 | 459 / 459 | 99% | 29.00 | 1107 / 1118 |
thymus | 100% | 886.06 | 653 / 653 | 99% | 24.02 | 598 / 605 |
stomach | 100% | 675.63 | 358 / 359 | 99% | 25.12 | 283 / 286 |
kidney | 100% | 825.38 | 89 / 89 | 99% | 25.52 | 888 / 901 |
liver | 100% | 1442.85 | 226 / 226 | 99% | 26.66 | 400 / 406 |
ovary | 100% | 924.56 | 180 / 180 | 98% | 18.56 | 423 / 430 |
bladder | 100% | 798.00 | 21 / 21 | 98% | 23.59 | 495 / 504 |
prostate | 100% | 836.03 | 245 / 245 | 98% | 33.27 | 493 / 502 |
esophagus | 99% | 517.30 | 1430 / 1445 | 99% | 24.91 | 181 / 183 |
uterus | 100% | 782.97 | 170 / 170 | 97% | 22.30 | 443 / 459 |
skin | 100% | 1343.23 | 1808 / 1809 | 92% | 23.54 | 435 / 472 |
adipose | 100% | 905.71 | 1204 / 1204 | 0% | 0 | 0 / 0 |
spleen | 100% | 715.05 | 241 / 241 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 669.78 | 1331 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 97% | 15.79 | 28 / 29 |
heart | 97% | 420.56 | 831 / 861 | 0% | 0 | 0 / 0 |
muscle | 96% | 319.22 | 767 / 803 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 93% | 18.18 | 42 / 45 |
peripheral blood | 77% | 456.55 | 713 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 75% | 10.13 | 60 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0043647 | Biological process | inositol phosphate metabolic process |
GO_0030282 | Biological process | bone mineralization |
GO_0030003 | Biological process | intracellular monoatomic cation homeostasis |
GO_0001503 | Biological process | ossification |
GO_0005615 | Cellular component | extracellular space |
GO_0005886 | Cellular component | plasma membrane |
GO_0070062 | Cellular component | extracellular exosome |
GO_0005788 | Cellular component | endoplasmic reticulum lumen |
GO_0030351 | Molecular function | inositol-1,3,4,5,6-pentakisphosphate 3-phosphatase activity |
GO_0016158 | Molecular function | 3-phytase activity |
GO_0051717 | Molecular function | inositol-1,3,4,5-tetrakisphosphate 3-phosphatase activity |
GO_0003993 | Molecular function | acid phosphatase activity |
GO_0034417 | Molecular function | bisphosphoglycerate 3-phosphatase activity |
GO_0016312 | Molecular function | inositol bisphosphate phosphatase activity |
GO_0008707 | Molecular function | 4-phytase activity |
GO_0046030 | Molecular function | inositol trisphosphate phosphatase activity |
GO_0052826 | Molecular function | inositol hexakisphosphate 2-phosphatase activity |
GO_0052827 | Molecular function | inositol pentakisphosphate phosphatase activity |
GO_0030352 | Molecular function | inositol-1,4,5,6-tetrakisphosphate 6-phosphatase activity |
GO_0052745 | Molecular function | inositol phosphate phosphatase activity |
GO_0004446 | Molecular function | inositol-hexakisphosphate phosphatase activity |
GO_0005515 | Molecular function | protein binding |
Gene name | MINPP1 |
Protein name | Multiple inositol polyphosphate phosphatase 1 (EC 3.1.3.62) (2,3-bisphosphoglycerate 3-phosphatase) (2,3-BPG phosphatase) (EC 3.1.3.80) |
Synonyms | MIPP UNQ900/PRO1917 |
Description | FUNCTION: Multiple inositol polyphosphate phosphatase that hydrolyzes 1D-myo-inositol 1,3,4,5,6-pentakisphosphate (InsP5[2OH]) and 1D-myo-inositol hexakisphosphate (InsP6) to a range of less phosphorylated inositol phosphates. This regulates the availability of these various small molecule second messengers and metal chelators which control many aspects of cell physiology . Has a weak in vitro activity towards 1D-myo-inositol 1,4,5-trisphosphate which is unlikely to be physiologically relevant . By regulating intracellular inositol polyphosphates pools, which act as metal chelators, it may control the availability of intracellular calcium and iron, which are important for proper neuronal development and homeostasis . May have a dual substrate specificity, and function as a 2,3-bisphosphoglycerate 3-phosphatase hydrolyzing 2,3-bisphosphoglycerate to 2-phosphoglycerate. 2,3-bisphosphoglycerate (BPG) is formed as part of the Rapoport-Luebering glycolytic bypass and is a regulator of systemic oxygen homeostasis as the major allosteric effector of hemoglobin . . |
Accessions | ENST00000371994.8 [Q9UNW1-2] Q9UNW1 ENST00000536010.1 [Q9UNW1-4] ENST00000371996.9 [Q9UNW1-1] |